Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

Jietao Lin MD; Lingling Sun MD; Hanrui Chen MD; Wenmin Chen MM; Zexin Zhang MM; Yang Cao MD; Lizhu Lin MD

doi:10.1177/15347354231185109

Integrative Cancer Therapies (Jul 2023)

Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

Jietao Lin MD,
Lingling Sun MD,
Hanrui Chen MD,
Wenmin Chen MM,
Zexin Zhang MM,
Yang Cao MD,
Lizhu Lin MD

Affiliations

Jietao Lin MD: Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Lingling Sun MD: Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Hanrui Chen MD: Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Wenmin Chen MM: Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Zexin Zhang MM: Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Yang Cao MD: Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Lizhu Lin MD: Center of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

DOI: https://doi.org/10.1177/15347354231185109
Journal volume & issue: Vol. 22

Abstract

Read online

Introduction: This planned multicenter observational study will evaluate the overall survival of those undergoing integrated Chinese and Western medicine for stage IIIb-IVb non-small cell lung cancer and analyze the factors related to the prognosis. Method and Analysis: The prospective cohort will enroll patients with stage IIIb-IVb NSCLC from March 1, 2019, to December 31, 2025, and follow them for 5 years. We plan to collect data on the patients’ demographics, treatment, overall survival, and factors related to the prognosis. Ethics and Dissemination: The institutional review board and ethics committee reviewed the study protocol. All patients will provide informed consent before enrollment. Trial registration number: ChiCTR1900021430

Published in Integrative Cancer Therapies

ISSN: 1534-7354 (Print); 1552-695X (Online)
Publisher: SAGE Publishing
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://journals.sagepub.com/home/ict

About the journal